ACAD — ACADIA PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1070494 ·
Last close
$20.68
Market Cap
$3.56B
52W High
$30.96
52W Low
$19.69
ADV30
1,759,230
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 307,959,000 279,643,000 37,836,000 31,500,000 1,742,900,000 384,985,000 436,291,000
Mar 2026 268,062,000 243,271,000 -4,616,000 3,637,000 1,605,230,000 282,212,000 357,164,000
Dec 2025 283,989,000 257,764,000 17,391,000 273,568,000 1,564,195,000 177,695,000 336,805,000
Sep 2025 278,633,000 256,986,000 35,756,000 71,779,000 1,330,771,000 257,996,000 413,499,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$123,494,000
Investing CF
$-112,234,000
Financing CF
$52,276,000
CapEx
$-104,735,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.20
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,778,249,000
Inventory
$32,372,000
Receivables
$166,330,000
ST Investments
$571,489,000
EBIT TTM
$86,367,000
Pretax Income TTM
$121,368,000
Interest Exp TTM
—
Analysts
20

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,138,643,968
EBITDA
$98,392,000
Free Cash Flow
$68,647,000
Enterprise Value
$3,912,642,560
Total Cash
$956,473,984
Total Debt
$73,854,000
Shares Out
172,305,518
Trailing EPS
$2.23
Book Value
$7.59
ROE
35.7%
ROA
3.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,071,505,000 104,811,000 391,000,000 1,564,195,000 336,805,000 1,227,390,000 109,836,000
Dec 2024 957,797,000 84,279,000 226,451,000 1,187,756,000 454,963,000 732,793,000 157,719,000
Dec 2023 726,437,000 -73,379,000 -61,286,000 748,956,000 317,201,000 431,755,000 16,702,000
Dec 2022 517,235,000 -223,596,000 -215,975,000 587,812,000 187,399,000 400,413,000 -114,035,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.89

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $22.00 · spot: $20.68 · call volume: 8,341 · put volume: 2,741
Expected Move to 2026-10-16: ±$1.90 (9.19%) — implied range $18.78 – $22.58 · ATM straddle on $21.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
XENE Xenon Pharmaceuticals Inc. $3.58B $36.94 —
IDYA IDEAYA Biosciences, Inc. $3.54B $36.69 —
OGN Organon & Co. $3.61B $13.73 —
KNSA Kiniksa Pharmaceuticals International, plc $3.63B $75.08 —
LEGN Legend Biotech Corp $3.72B $19.11 —

News headlines (Yahoo Finance, 1h cache)

Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop
2026-09-27 07:09 · Yahoo
ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets
2026-09-25 15:22 · Yahoo
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss
2026-09-25 15:01 · Yahoo
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
2026-09-25 13:21 · Yahoo
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13%
2026-09-25 03:26 · Yahoo
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
2026-09-24 22:41 · Yahoo
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%
2026-09-24 21:51 · Yahoo
Bears Chase Down Acadia Pharma After Surprise Alzheimer's Setback
2026-09-24 20:13 · Yahoo
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data
2026-09-24 15:25 · Yahoo
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial
2026-09-24 15:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.